What is LCTX stock price today?

LCTX (Lineage Cell Therapeutics Inc) stock is trading at $1.71 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is LCTX stock going up or down today?

LCTX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy LCTX stock now?

The decision to buy LCTX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is LCTX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for LCTX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is LCTX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if LCTX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is LCTX's P/E ratio?

P/E ratio data for LCTX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is LCTX's market cap?

LCTX (Lineage Cell Therapeutics Inc) has a market capitalization of $0.41 billion, making it a small-cap stock.

What is LCTX's price to book ratio?

LCTX trades at a price-to-book (P/B) ratio of 9.11, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does LCTX pay dividends?

LCTX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is LCTX's dividend yield?

LCTX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is LCTX stock a good long-term investment?

LCTX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is LCTX's revenue growth rate?

LCTX has shown revenue growth of 1.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for LCTX are available on our dashboard with complete income statement analysis.

What are the risks of investing in LCTX?

Key risks for LCTX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does LCTX compare to its competitors?

Compare LCTX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize LCTX's performance and positioning.

What is LCTX's stock price target for 2026?

Our AI model provides price targets for LCTX based on fundamental analysis: Bull case $2.22 (+30%), Base case $1.97 (+15%), Bear case $1.54 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about LCTX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for LCTX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is LCTX's next earnings report?

LCTX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

LCTX - Lineage Cell Therapeutics Inc

NYSE * Health Care * Biotechnology

$1.71

+$0.07 (+4.27%)

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

LCTX Key Statistics

Market Cap

$408.50M

P/B Ratio

9.11

EPS

$-0.28

Revenue Growth

+1.3%

Employees

How LCTX Compares to Peers

LCTX has the fastest revenue growth among competitors

LCTX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
LCTX(This stock)	$408.50M	N/A	1%	0.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Lineage Cell Therapeutics Inc Company Information

Headquarters: California; U.S.A
Website: www.lineagecell.com
Sector: Health Care
Industry: Biotechnology

LCTX - Lineage Cell Therapeutics Inc

About Lineage Cell Therapeutics Inc

LCTX Key Statistics

How LCTX Compares to Peers

Lineage Cell Therapeutics Inc Company Information

LCTX Lician Score

LCTX Financial Snowflake

Upcoming Events for LCTX